-
Patented Medicines Expenditure in Canada 1990-2018: Are government price controls justified? »
-
COVID-19 POLICY PAPERS »
-
Coverage of new medicines in Federal-Provincial public drug plans 2009-2018 »
-
Evidence that innovative medicines improve health and economic outcomes. »
-
Close the Gaps: Patient Benefits and Taxpayer Costs of 3 Pharmacare Options. »
-
VIDEO - National Pharmacare Facts. »
-
Out-of-pocket prescription drug costs: What are the implications for National Pharmacare? »
-
Consequences of over-regulating the prices of new drugs in Canada »
-
Costs without benefits for patients? Non-medical spending in Canada’s public health system »
Tweets
Tweets by @CHPI1
Latest
-
Clinical Trials in Canada: Worrying Signs Remain Despite PMPRB’s Superficial Response
Nigel S B Rawson, PhD »
-
National Strategy for Drugs for Rare Diseases should Prioritize Patients not Cost Containment
Nigel S B Rawson, PhD and John Adams, BA »
-
Clinical Trials in Canada: Worrying Signs that PMPRB Changes will Impact Research Investment
Nigel S B Rawson, PhD EN/FR »
-
Patented Medicines Expenditure in Canada 1990-2018
Are government price controls justified by the cost of innovative pharmaceuticals? CHPI RESEARCH REPORT »
-
Canada’s Vaccine Development Capacity and the Federal Government’s Management of COVID-19
Paul Lucas, Retired President and CEO GlaxoSmithKline. »
-
Ensuring early access to a COVID-19 vaccine in Canada.
Policy solutions include Regulatory Harmonization, Fair Market Prices, and Intellectual Property Rights. Brett Skinner, PhD. »
